Invitris
Creating new protein-based drugs at scale
Invitris radically simplifies how we create novel biological drugs. Our patent-pending technology platform turns DNA into synthetic proteins and was recently featured in the Science magazine. It makes creating new drugs >10,000x more efficient at <100x lower costs of material. Our killer application is enabling the newest generation of synthetic bacteriophages to combat antibiotic-resistant infections, which are threatening to cause more deaths than all cancers combined.
Jobs at Invitris
Company Launches
INVITRIS - Simplifying drug development & manufacturing
Active Founders
Patrick Grossmann
My hearts are entrepreneurship & science, originally trained as bioinformatician at the Harvard Medical School and ETH Zurich amongst other schools. I earned a PhD and MBA, and highly enjoy opportunities to improve the world with science-based products. I co-founded Invitris to radically simplify drug development to stop antibiotic-resistance, which has the potential to become the dominating health-economic challenge in this century.
Kilian Vogele
Kilian, the CTO and co-founder of Invitris, is responsible for driving innovation and development within the company. With a PhD in synthetic biology from TUM and a track record of 5 patents, his expertise has been instrumental in creating Invitris' groundbreaking technology.
